QCast Episode 56: Bayesian Clinical Trial Design

Bayesian clinical trial design provides a structured way to update evidence as new trial data become available. In this QCast episode, co-hosts Jullia and Tom explain how priors, likelihoods and posterior distributions support decisions about treatment effects, dose levels, trial continuation and adaptation. They also clarify how posterior probability differs from predictive probability and why Bayesian and frequentist methods answer questions in different ways.

The statistical model is only one part of the design. Interim decisions depend on timely data entry, query resolution, programming, controlled access to unblinded results and clear implementation processes. Priors and external data also require careful assessment because a large historical dataset may contribute little when the population, endpoint or trial setting does not match the current study.

🎧 Listen to the Episode:

Key Takeaways

How Bayesian updating supports clinical decisions
A Bayesian analysis combines prior information with current trial data to form a posterior distribution. This allows teams to estimate the probability that a treatment is better than control or exceeds a clinically meaningful threshold. Predictive probability can then estimate the likelihood of final trial success if recruitment and follow-up continue.

Why external evidence needs careful control
Historical trials, registries and natural history data can inform a prior, but their value depends on comparability with the current study. Effective sample size reflects the information contributed by the prior rather than the number of patients in the external dataset. Robust borrowing methods and sensitivity analyses can reduce the influence of conflicting evidence and show how dependent the conclusion is on prior assumptions.

How simulation connects design with delivery
Simulation tests the proposed design across plausible treatment effects, recruitment patterns, missing data assumptions and conflicts between prior and current evidence. It can estimate the chance of correct and incorrect decisions, early stopping and different sample-size paths. These results help teams set decision rules and confirm that the operational plan can support each planned adaptation.

Full Transcript

Jullia

Welcome to QCast, the show where biometric expertise meets data-driven dialogue. I’m Jullia.

Tom

I’m Tom, and in each episode, we dive into the methodologies, case studies, regulatory shifts, and industry trends shaping modern drug development.

Jullia

Whether you’re in biotech, pharma or life sciences, we’re here to bring you practical insights straight from a leading biometrics CRO. Let’s get started.

Tom

Now Bayesian clinical trial design can sound more complicated than it is. What’s the simplest way to describe what makes a design Bayesian?

Jullia

It starts with what we know before the current trial data are analysed, then updates that knowledge as new evidence arrives. The starting information is represented by a prior distribution. The trial data contribute the likelihood, and the two combine to form the posterior distribution, which is our updated view of the treatment effect.

Tom

Some people hear “prior” and assume the analysis is built around someone’s opinion. Is that right?

Jullia

It can be, if the prior is poorly chosen or weakly justified. But a prior might come from earlier trials, registry data, natural history evidence or previous phases of the same programme. Its source, relevance and influence should be explicit, rather than quietly embedded in planning assumptions.

Tom

Once the posterior is available, what can the team actually ask of it?

Jullia

They can make direct probability statements about the treatment effect. For example, what’s the probability that the treatment is better than control, or that the benefit exceeds a clinically meaningful threshold? A treatment can look likely to help while the size of that benefit remains too uncertain for the next development decision.

Tom

Predictive probability often appears alongside posterior probability. How are they different?

Jullia

A posterior probability describes what the evidence suggests now. A predictive probability asks what’s likely to happen by the end if the trial continues. At an interim review, current data might suggest benefit, but the predictive probability of final success could still be low if further recruitment is unlikely to resolve the uncertainty.

Tom

So this isn’t simply another way to calculate a p-value?

Jullia

No. Bayesian analysis can assign probability to a treatment effect, conditional on the model, prior and observed data. Frequentist measures such as p-values and confidence intervals have a different repeated-sampling interpretation, even when both frameworks address the same clinical question.

Tom

Is one framework better?

Jullia

Not in general. A fixed frequentist design may suit a straightforward question with one final decision point. Bayesian methods become useful when a trial needs planned learning during conduct, formal use of relevant external information, or probability-based decisions on doses, treatment arms or continuation.

Tom

Give me an example of that planned learning.

Jullia

Think about an early dose-finding study with several dose levels. At a planned review, the team may use accumulating safety and activity data to decide whether a dose should continue, stop or expand. That only works if adverse events, laboratory data and dosing records have been entered, cleaned and reviewed in time.

Tom

So the model may be sophisticated, but a late lab upload or unresolved query can still delay the decision?

Jullia

Yes. Bayesian design doesn’t remove ordinary trial dependencies. The data cut, query turnaround, programming workflow and access to interim results must support the decision timetable. If an adaptation changes recruitment or dosing, the operational teams also need a controlled way to implement it. Simulation, data flow, programming and governance should be planned together, because the design only works if the trial can execute it reliably.

Tom

Let’s return to priors. How does a team decide how much influence historical evidence should have?

Jullia

They look at how closely it matches the current study. Population, endpoint definition, standard of care, geography, follow-up and trial conduct can all affect comparability. A large historical dataset may contribute little if it’s old, inconsistent or poorly aligned with the current question.

Tom

Is that where effective sample size comes in?

Jullia

Yes. It expresses the information contributed by a prior in terms roughly comparable with additional participants. It isn’t simply the number of patients in the historical study. The usable contribution depends on the prior’s precision, relevance and consistency with the current data.

Tom

What happens if the new results conflict with the historical evidence? Does the prior keep pulling the answer back?

Jullia

That depends on the model. Robust or dynamic borrowing approaches can reduce the influence of external data when conflict appears. Sensitivity analyses should also show whether the conclusion changes under weaker, stronger or alternative priors. Savings aren’t guaranteed, and poorly matched external data can create bias rather than useful information.

Tom

Where does borrowing tend to be most useful?

Jullia

Rare disease and paediatric studies are clear examples because recruitment may be difficult or ethically constrained. It can also support platform trials, historical control analyses and programmes with relevant evidence from earlier phases. The argument still has to be clinical as well as statistical.

Tom

Beyond stopping and dose decisions, what other adaptations can a Bayesian design support?

Jullia

A pre-specified design might re-estimate sample size, drop an ineffective arm, enrich a subgroup or change randomisation probabilities. These options can help in multi-arm or platform trials, but delayed outcomes, temporal drift and non-concurrent controls can affect the analysis. Those risks need attention before enrolment begins.

Tom

I want to challenge another assumption. Because Bayesian evidence updates as data accumulate, can the team look whenever it wants and make a decision?

Jullia

No. Interim reviews still need planned timing, controlled access and pre-defined rules. The protocol should state what can change, when it can change, who can see unblinded results and how the decision will be communicated. Independent oversight may be needed to keep responsibilities separate.

Tom

How do you know beforehand whether those rules will behave sensibly?

Jullia

Through simulation. Teams run the proposed design repeatedly under plausible treatment effects, recruitment patterns, missing data assumptions and prior-data conflicts. They examine operating characteristics such as the chance of a correct decision, the chance of declaring success incorrectly, expected sample size and how often the trial stops early. An adaptive trial may have a maximum sample size, but the actual number can vary across possible paths. Simulations can show the expected sample size under different treatment effects and the range created by early stopping or adaptation.

Tom

So the simulation is a stress test for the decision system.

Jullia

Yes, and it should include unfavourable scenarios, not only those that make the design look efficient. A futility rule could stop an effective treatment too soon. A success rule could stop on evidence that wouldn’t remain convincing, so those risks need to be estimated and calibrated.

Tom

Once those rules and operating characteristics are defined, how are regulators likely to view the design?

Jullia

Bayesian methods can be acceptable when the design is transparent, pre-specified and supported by credible operating characteristics. Regulators will want to understand the prior, model, thresholds, sensitivity analyses, software and performance under adverse scenarios. Early engagement is particularly important when the primary inference uses informative priors, external controls or complex adaptations.

Tom

Let’s address one last misconception as we close. Does Bayesian analysis mean the study can dispense with randomisation, blinding or concurrent controls?

Jullia

No. It changes how evidence is modelled and updated. It doesn’t replace sound design or bias control. Randomisation, blinding, clear endpoint definitions and concurrent controls may still be central to the trial’s credibility.

Tom

If you had to leave listeners with a brief recap, what should stay with them?

Jullia

Bayesian design is most useful when it improves a real clinical decision, rather than adding complexity for its own sake. Its assumptions need to be visible, especially the prior and any external borrowing. And the design must be simulated and operationally planned before the trial begins, because flexible decisions still require disciplined rules.

With that, we’ve come to the end of today’s episode on Bayesian clinical trial design. If you found this discussion useful, don’t forget to subscribe to QCast so you never miss an episode and share it with a colleague. And if you’d like to learn more about how Quanticate supports data-driven solutions in clinical trials, head to our website or get in touch.

Tom

Thanks for tuning in, and we’ll see you in the next episode.

About QCast

QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.

Subscribe to QCast on Apple Podcasts or Spotify to never miss an episode.